

Onorina Berardicurti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3740118/publications.pdf>

Version: 2024-02-01

72
papers

2,527
citations

172207

29
h-index

214527

47
g-index

72
all docs

72
docs citations

72
times ranked

3259
citing authors

#	ARTICLE	IF	CITATIONS
1	The Role of IL-1 β in the Bone Loss during Rheumatic Diseases. <i>Mediators of Inflammation</i> , 2015, 2015, 1-10.	1.4	146
2	Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. <i>Arthritis Research and Therapy</i> , 2013, 15, R172.	1.6	143
3	Beyond the joints, the extra-articular manifestations in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2021, 20, 102735.	2.5	135
4	Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. <i>BMC Medicine</i> , 2016, 14, 194.	2.3	130
5	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritis, etc.) <i>TJ ETQq1 1 0.784314 rgBT /Overlock 11</i>	2.5	107
6	Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. <i>Autoimmunity Reviews</i> , 2019, 18, 93-106.	2.5	101
7	Tocilizumab for the treatment of adult-onset Still's disease: results from a case series. <i>Clinical Rheumatology</i> , 2014, 33, 49-55.	1.0	84
8	The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor- β and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist. <i>Journal of Rheumatology</i> , 2015, 42, 1808-1816.	1.0	82
9	Severe COVID-19, Another Piece in the Puzzle of the Hyperferritinemic Syndrome. An Immunomodulatory Perspective to Alleviate the Storm. <i>Frontiers in Immunology</i> , 2020, 11, 1130.	2.2	79
10	Rheumatic manifestations of COVID-19: a systematic review and meta-analysis. <i>BMC Rheumatology</i> , 2020, 4, 65.	0.6	78
11	Interstitial lung disease in systemic sclerosis: current and future treatment. <i>Rheumatology International</i> , 2017, 37, 853-863.	1.5	76
12	Cytokine storm syndrome in severe COVID-19. <i>Autoimmunity Reviews</i> , 2020, 19, 102562.	2.5	72
13	Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers. <i>Autoimmunity Reviews</i> , 2017, 16, 16-21.	2.5	65
14	Is minor salivary gland biopsy more than a diagnostic tool in primary Sjögren's syndrome? Association between clinical, histopathological, and molecular features: A retrospective study. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 314-324.	1.6	61
15	Macrophage activation syndrome in Still's disease: analysis of clinical characteristics and survival in paediatric and adult patients. <i>Clinical Rheumatology</i> , 2017, 36, 2839-2845.	1.0	53
16	Vitamin D and systemic lupus erythematosus - The hype and the hope. <i>Autoimmunity Reviews</i> , 2018, 17, 19-23.	2.5	52
17	Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease. <i>Autoimmunity Reviews</i> , 2015, 14, 429-437.	2.5	46
18	IL-1 β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone?. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 849-855.	1.3	46

#	ARTICLE	IF	CITATIONS
19	Perivascular Cells in Diffuse Cutaneous Systemic Sclerosis Overexpress Activated ADAM12 and Are Involved in Myofibroblast Transdifferentiation and Development of Fibrosis. <i>Journal of Rheumatology</i> , 2016, 43, 1340-1349.	1.0	45
20	Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis. <i>Medicine (United States)</i> , 2017, 96, e7896.	0.4	42
21	Poor clinical response in rheumatoid arthritis is the main risk factor for diabetes development in the short-term: A 1-year, single-centre, longitudinal study. <i>PLoS ONE</i> , 2017, 12, e0181203.	1.1	42
22	Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligenceâ€“radiological differences. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1152-1155.	0.5	41
23	Increased Cardiovascular Events and Subclinical Atherosclerosis in Rheumatoid Arthritis Patients: 1 Year Prospective Single Centre Study. <i>PLoS ONE</i> , 2017, 12, e0170108.	1.1	41
24	Pro-inflammatory properties of H-ferritin on human macrophages, ex vivo and in vitro observations. <i>Scientific Reports</i> , 2020, 10, 12232.	1.6	38
25	Parenchymal lung disease in adult onset Stillâ€™s disease: an emergent marker of disease severityâ€™ characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients. <i>Arthritis Research and Therapy</i> , 2020, 22, 151.	1.6	38
26	The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Expertsâ€™ Consensus. <i>Autoimmunity Reviews</i> , 2021, 20, 102738.	2.5	38
27	Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets?. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 1041-1047.	1.3	36
28	IL-1 inhibition improves insulin resistance and adipokines in rheumatoid arthritis patients with comorbid type 2 diabetes. <i>Medicine (United States)</i> , 2019, 98, e14587.	0.4	36
29	Severe COVID-19 and related hyperferritinaemia: more than an innocent bystander?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1515-1516.	0.5	36
30	Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: a new potential target for antifibrotic therapy. <i>Arthritis Research and Therapy</i> , 2018, 20, 223.	1.6	29
31	Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature. <i>Journal of Medical Case Reports</i> , 2015, 9, 123.	0.4	28
32	Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study. <i>Medicine (United States)</i> 100(10):e27177. doi:10.1093/med/100/10/e27177	0.4	27
33	The Emerging Role of IL-1 Inhibition in Patients Affected by Rheumatoid Arthritis and Diabetes. <i>Reviews on Recent Clinical Trials</i> , 2018, 13, 210-214.	0.4	26
34	Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis. <i>Arthritis Research and Therapy</i> , 2021, 23, 213.	1.6	25
35	Impaired Cav-1 expression in SSc mesenchymal cells upregulates VEGF signaling: a link between vascular involvement and fibrosis. <i>Fibrogenesis and Tissue Repair</i> , 2014, 7, 13.	3.4	24
36	Dissecting the clinical heterogeneity of adult-onset Stillâ€™s disease: results from a multi-dimensional characterization and stratification. <i>Rheumatology</i> , 2021, 60, 4844-4849.	0.9	23

#	ARTICLE	IF	CITATIONS
37	Macitentan inhibits the transforming growth factor- β 2 profibrotic action, blocking the signaling mediated by the ETR/T β 2RI complex in systemic sclerosis dermal fibroblasts. <i>Arthritis Research and Therapy</i> , 2015, 17, 247.	1.6	22
38	Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study. <i>Clinical Rheumatology</i> , 2017, 36, 251-260.	1.0	22
39	Mortality in tocilizumab-treated patients with COVID-19: a systematic review and meta-analysis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 1247-1254.	0.4	22
40	The role of extracellular matrix components in angiogenesis and fibrosis: Possible implication for Systemic Sclerosis. <i>Modern Rheumatology</i> , 2018, 28, 922-932.	0.9	21
41	Adipocytokines in Rheumatoid Arthritis: The Hidden Link between Inflammation and Cardiometabolic Comorbidities. <i>Journal of Immunology Research</i> , 2018, 2018, 1-10.	0.9	20
42	Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies. <i>Cytotherapy</i> , 2015, 17, 832-849.	0.3	19
43	Mesenchymal stem cells of Systemic Sclerosis patients, derived from different sources, show a profibrotic microRNA profiling. <i>Scientific Reports</i> , 2019, 9, 7144.	1.6	18
44	Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension. <i>Arthritis Research and Therapy</i> , 2020, 22, 127.	1.6	18
45	Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still's disease. <i>Rheumatology</i> , 2022, 61, 4124-4129.	0.9	16
46	Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies very early cardiac involvement in systemic sclerosis patients of recent onset. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 1247-1260.	0.9	15
47	Cytokine profile, ferritin and multi-visceral involvement characterize macrophage activation syndrome during adult-onset Still's disease. <i>Rheumatology</i> , 2022, 62, 321-329.	0.9	15
48	Glucocorticoids in rheumatoid arthritis: the silent companion in the therapeutic strategy. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 593-604.	1.3	13
49	Epidermal Growth Factor Like-domain 7 and miR-126 are abnormally expressed in diffuse Systemic Sclerosis fibroblasts. <i>Scientific Reports</i> , 2019, 9, 4589.	1.6	12
50	The wide spectrum of Kawasaki-like disease associated with SARS-CoV-2 infection. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 1205-1215.	1.3	12
51	Peripheral Nervous System Involvement in Sjögren's Syndrome: Analysis of a Cohort From the Italian Research Group on Sjögren's Syndrome. <i>Frontiers in Immunology</i> , 2021, 12, 615656.	2.2	12
52	The joint involvement in adult onset Still's disease is characterised by a peculiar magnetic resonance imaging and a specific transcriptomic profile. <i>Scientific Reports</i> , 2021, 11, 12455.	1.6	10
53	The clinical heterogeneity of adult onset Still's disease may underlie different pathogenic mechanisms. Implications for a personalised therapeutic management of these patients. <i>Seminars in Immunology</i> , 2021, 58, 101632.	2.7	10
54	Cardiovascular Disease in Primary Sjögren's Syndrome. <i>Reviews on Recent Clinical Trials</i> , 2018, 13, 164-169.	0.4	8

#	ARTICLE	IF	CITATIONS
55	Immunofibroblasts regulate LT α 3 expression in tertiary lymphoid structures in a pathway dependent on ICOS/ICOSL interaction. <i>Communications Biology</i> , 2022, 5, 413.	2.0	8
56	Searching for a good model for systemic sclerosis: the molecular profile and vascular changes occurring in UCD-200 chickens strongly resemble the early phase of human systemic sclerosis. <i>Archives of Medical Science</i> , 2016, 4, 828-843.	0.4	7
57	Persistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondyloarthritis. <i>Scientific Reports</i> , 2022, 12, 7498.	1.6	7
58	Tofacitinib May Inhibit Myofibroblast Differentiation from Rheumatoid-Fibroblast-like Synoviocytes Induced by TGF- β 2 and IL-6. <i>Pharmaceuticals</i> , 2022, 15, 622.	1.7	7
59	Association Between Minor Salivary Gland Biopsy During Sjögren's Syndrome and Serologic Biomarkers: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 686457.	2.2	6
60	Laboratory Assessment of Patients with Suspected Rheumatic Musculoskeletal Diseases: Challenges and Pitfalls. <i>Current Rheumatology Reviews</i> , 2018, 15, 27-43.	0.4	6
61	Impact of smoking habit on adult-onset Still's disease prognosis, findings from a multicentre observational study. <i>Clinical Rheumatology</i> , 2022, 41, 641-647.	1.0	6
62	Evaluating the multivisceral involvement on adult-onset Still's disease to retrieve imaging-based differences in patients with and without macrophage activation syndrome: results from a single-centre observational study. <i>Clinical Rheumatology</i> , 2021, 40, 3971-3978.	1.0	5
63	The incidence of cardiovascular events in Italian patients with systemic lupus erythematosus is lower than in North European and American cohorts. <i>Medicine (United States)</i> , 2018, 97, e0370.	0.4	4
64	Use of Rituximab in the Management of Sjögren's Syndrome. <i>Current Treatment Options in Rheumatology</i> , 2015, 1, 277-291.	0.6	3
65	The hyper-expression of NLRP4 characterizes the occurrence of macrophage activation syndrome assessing STING pathway in adult-onset Still's disease. <i>Clinical and Experimental Immunology</i> , 2022, 208, 95-102.	1.1	3
66	Unenhanced Cardiac Magnetic Resonance may improve detection and prognostication of an occult heart involvement in asymptomatic patients with systemic sclerosis. <i>Scientific Reports</i> , 2022, 12, 5125.	1.6	3
67	Incidence of venous thromboembolism in rheumatoid arthritis, results from a "real-life" cohort and an appraisal of available literature. <i>Medicine (United States)</i> , 2021, 100, e26953.	0.4	2
68	Italian recommendations for influenza and pneumococcal vaccination in adult patients with autoimmune rheumatic diseases. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 245-256.	0.4	2
69	Response to: "Correspondence on Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence" radiological differences" by Ruscitti et al" by Chen et al". <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e221-e221.	0.5	1
70	Long-term safety of rituximab in primary Sjögren's syndrome: the experience of a single centre. <i>Journal of Rheumatology</i> , 2021, , jrheum.210441.	1.0	1
71	Erratum to "The minor salivary gland biopsy more than a diagnostic tool in primary Sjögren's syndrome? Association between clinical, histopathological, and molecular features: A retrospective study" [Semin Arthritis Rheum 44 (2014) 314-324]. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, e23.	1.6	0
72	Duration of clinical remission and low disease activity impacts on quality of life and its domains in psoriatic arthritis patients: results from an Italian multicentre study. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.4	0